Company profile
Enedra Therapeutics
Checkmating Cancer Evolution - we're targeting the infrastructure that enables cancer cells to evolve
Financial period: 1 Aug 2024 to 31 Jul 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
SH01 | Transaction MzQ0NDgwNzgxMWFkaXF6a2N4
Published 25 Nov 2024 06:21
AP01 | Transaction MzQ0Mjc4NDY4NmFkaXF6a2N4
Published 12 Nov 2024 10:04
SH01 | Transaction MzQzODI3MjM2OGFkaXF6a2N4
Published 03 Oct 2024 08:57
DISS40 | Transaction MzQzMjkzNDQ0MmFkaXF6a2N4 | Paper/PDF filed
Published 25 Aug 2024 06:45
CS01 | Transaction MzQzMjkzNDQyNGFkaXF6a2N4
Published 21 Aug 2024 11:55
PSC04 | Transaction MzQzMjc1NjExN2FkaXF6a2N4
Published 21 Aug 2024 10:12
CH01 | Transaction MzQzMjc0MjU0NmFkaXF6a2N4
Published 21 Aug 2024 08:54
GAZ1 | Transaction MzQzMTk0MjgyOWFkaXF6a2N4 | Paper/PDF filed
Published 16 Aug 2024 12:38
PSC04 | Transaction MzQzMjY0MTg3NmFkaXF6a2N4
Published 19 Aug 2024 15:27
CH01 | Transaction MzQzMjY0MDg5OGFkaXF6a2N4
Published 19 Aug 2024 15:19
Company registered at Companies House
1 Nov 2024 to 31 Oct 2025
Cancer is the leading cause of death in the UK, a significant and hard to tackle healthcare challenge. Whilst targeted and immune therapies are improving survival, large studies in tumour evolution reveal that the driver of poor patient survival is DNA chromosomal instability (CIN) and tumour heterogeneity. This instability progressively enables tumours t...
